Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Pharmaceuticals, Inc.

http://www.amneal.com

Latest From Amneal Pharmaceuticals, Inc.

Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Approval Standards

Amneal Makes It Three With Pegfilgrastim Approval

Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.

Biosimilars Approvals

Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities

Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.

Sales & Earnings Generic Drugs

Amneal Sets $200m Sales Ambition For Biosimilar Trio

Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Amedra Pharmaceuticals LLC
    • Amneal Pharmaceuticals, LLC
    • CorePharma LLC
    • Gemini Laboratories, LLC
    • Impax Generics
    • Impax Laboratories, Inc. (IPXL)
    • Impax Specialty Pharma
    • Lineage Therapeutics Inc.
    • Tower Holdings, Inc.
UsernamePublicRestriction

Register